1. Inhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer
- Author
-
Steven M Nguyen, Aurelio Castrellon, and Luis E. Raez
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,biology ,business.industry ,Kinase ,Estrogen receptor ,medicine.disease ,Bioinformatics ,Metastatic breast cancer ,Clinical trial ,Serine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Breast cancer ,Cyclin-dependent kinase ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Medicine ,Pediatrics, Perinatology, and Child Health ,business ,Hormone - Abstract
Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ threonine kinases that play a key role in regulating cell cycle progression. In this review, we discuss the currently approved and under investigation CDK 4/6 inhibitors, in addition to their preclinical data and clinical trials that demonstrated their benefit in the treatment of HR+ breast cancer.
- Published
- 2017
- Full Text
- View/download PDF